Atirmociclib (PF-07220060) is a next-generation, highly selective CDK4 inhibitor designed to minimize off-target effects.
By enhancing CDK4 selectivity over CDK6, atirmociclib reduces neutropenia risk, a common dose-limiting toxicity of dual CDK4/6 inhibitors.
Superior CDK4 target coverage enables deeper anti-tumor responses in HR+/HER2− breast cancer, where tumor cells rely primarily on CDK4.
Combination therapies further enhance atirmociclib’s efficacy and may overcome acquired resistance, expanding its clinical potential.
CDK4/6 inhibitors have transformed the treatment of hormone receptor-positive (HR+), HER2-negative (HER2−) breast cancer. However, current dual CDK4/6 inhibitors cause dose-limiting hematologic toxicities, particularly neutropenia, restricting their ability to fully suppress tumor cell proliferation.
Unlike tumor cells, which depend heavily on CDK4, hematopoietic cells rely more on CDK6, making CDK4 a more selective therapeutic target. Leveraging this insight, we developed atirmociclib (PF-07220060), a CDK4-selective inhibitor that minimizes neutrophil suppression while maintaining potent anti-tumor activity.
By achieving higher CDK4 inhibition at tolerated doses, atirmociclib induces stronger tumor regression compared to dual inhibitors, highlighting target coverage as a key determinant of efficacy. Additionally, we identify combination strategies that may enhance atirmociclib’s effectiveness and broaden its use in overcoming resistance.
This approach offers a promising advancement in precision oncology, optimizing CDK4 inhibition while reducing treatment-limiting side effects.